Genetics of familial and sporadic pancreatic cancer

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Signatures of mutational processes in human cancer

Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · see citing works

Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · see citing works

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

Conroy, T., Desseigne, F., Ychou, M., Bouché, O., Guimbaud, R., Bécouarn, Y., Adenis, A., Raoul, J.-L., Gourgou-Bourgade, S., de la Fouchardière, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1011923 · Cited by 7,810 · see citing works

Projecting Cancer Incidence and Deaths to 2030: The Unexpected Burden of Thyroid, Liver, and Pancreas Cancers in the United States

Rahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094 · see citing works

Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine

Von Hoff, D. D., Ervin, T., Arena, F. P., Chiorean, E. G., Infante, J., Moore, M., Seay, T., Tjulandin, S. A., Ma, W. W., Saleh, M. N., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1304369 · Cited by 6,712 · see citing works

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade

Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · see citing works

Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies

Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848 · see citing works

Genomic analyses identify molecular subtypes of pancreatic cancer

Bailey, P., Chang, D. K., Nones, K., Johns, A. L., Patch, A.-M., Gingras, M.-C., Miller, D. K., Christ, A. N., Bruxner, T. J. C., Quinn, M. C., et al. (2016) · Nature · doi:10.1038/nature16965 · Cited by 3,621 · see citing works

Olaparib for Metastatic Breast Cancer in Patients with a Germline <i>BRCA</i> Mutation

Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294 · see citing works

Efficacy of Larotrectinib in <i>TRK</i> Fusion–Positive Cancers in Adults and Children

Drilon, A., Laetsch, T. W., Kummar, S., DuBois, S. G., Lassen, U. N., Demetri, G. D., Nathenson, M., Doebele, R. C., Farago, A. F., Pappo, A. S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1714448 · Cited by 2,824 · see citing works

Detection and localization of surgically resectable cancers with a multi-analyte blood test

Cohen, J. D., Li, L., Wang, Y., Thoburn, C., Afsari, B., Danilova, L., Douville, C., Javed, A. A., Wong, F., Mattox, A., et al. (2018) · Science · doi:10.1126/science.aar3247 · Cited by 2,783 · see citing works

Whole genomes redefine the mutational landscape of pancreatic cancer

Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · see citing works

Distant metastasis occurs late during the genetic evolution of pancreatic cancer

Yachida, S., Jones, S., Bozic, I., Antal, T., Leary, R., Fu, B., Kamiyama, M., Hruban, R. H., Eshleman, J. R., Nowak, M. A., et al. (2010) · Nature · doi:10.1038/nature09515 · Cited by 2,502 · see citing works

<i>DPC4</i> , A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1

Hahn, S. A., Schutte, M., Shamsul Hoque, A. T. M., Moskaluk, C. A., da Costa, L. T., Rozenblum, E., Weinstein, C. L., Fischer, A., Yeo, C. J., Hruban, R. H., et al. (1996) · Science · doi:10.1126/science.271.5247.350 · Cited by 2,337 · see citing works

Virtual microdissection identifies distinct tumor- and stroma-specific subtypes of pancreatic ductal adenocarcinoma

Moffitt, R. A., Marayati, R., Flate, E. L., Volmar, K. E., Loeza, S. G. H., Hoadley, K. A., Rashid, N. U., Williams, L. A., Eaton, S. C., Chung, A. H., et al. (2015) · Nature Genetics · doi:10.1038/ng.3398 · Cited by 2,194 · see citing works

Talazoparib in Patients with Advanced Breast Cancer and a Germline <i>BRCA</i> Mutation

Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175 · see citing works

Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes

Almoguera, C., Shibata, D. K., Forrester, K., Wj, M., Arnheim, N., & Perucho, M. (1988) · Cell · doi:10.1016/0092-8674(88)90571-5 · Cited by 2,100 · see citing works

Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes

Initiative, A. P. C. G., Biankin, A. V., Waddell, N., Kassahn, K. S., Gingras, M.-C., Muthuswamy, L. B., Johns, A. L., Miller, D. K., Wilson, P. J., Patch, A.-M., et al. (2012) · Nature · doi:10.1038/nature11547 · Cited by 2,058 · see citing works

Integrated genomic characterization of pancreatic ductal adenocarcinoma

Raphael, B. J., Hruban, R. H., Aguirre, A. J., Moffitt, R. A., Yeh, J. J., Stewart, C., Robertson, A. G., Cherniack, A. D., Gupta, M., Getz, G., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.007 · Cited by 2,019 · see citing works

Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy

Collisson, E. A., Sadanandam, A., Olson, P., Gibb, W. J., Truitt, M., Gu, S., Cooc, J., Weinkle, J., Kim, G. E., Jakkula, L., et al. (2011) · Nature Medicine · doi:10.1038/nm.2344 · Cited by 1,967 · see citing works

Putting p53 in context

Kastenhuber, E. R., & Lowe, S. W. (2017) · Cell · doi:10.1016/j.cell.2017.08.028 · Cited by 1,906 · see citing works

Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation

Kaufman, B., Shapira‐Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M. L., Balmañà, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,707 · see citing works

Very high risk of cancer in familial Peutz–Jeghers syndrome

Giardiello, F. M., Brensinger, J. D., Tersmette, A. C., Goodman, S. N., Petersen, G. M., Booker, S. V., Cruz–Correa, M., & Offerhaus, G. J. A. (2000) · Gastroenterology · doi:10.1053/gast.2000.20228 · Cited by 1,435 · see citing works

Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Royal, R. E., Levy, C. L., Turner, K. M., Mathur, A., Hughes, M. S., Kammula, U. S., Sherry, R. M., Topalian, S. L., Yang, J. C.-H., Lowy, I., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181eec14c · Cited by 1,266 · see citing works

Cancer Incidence in BRCA1 mutation carriers.

Thompson, D., & Easton, D. (2002) · Journal of the National Cancer Institute · doi:10.1093/jnci/94.18.1358 · Cited by 1,231 · see citing works

Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma

Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M. E. M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., & Kern, S. E. (1994) · Nature Genetics · doi:10.1038/ng0994-27 · Cited by 1,132 · see citing works

Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets

Witkiewicz, A. K., McMillan, E. A., Balaji, U., Baek, G., Lin, W.-C., Mansour, J., Mollaee, M., Wagner, K.-U., Koduru, P., Yopp, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms7744 · Cited by 1,115 · see citing works

Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer

Tiriac, H., Belleau, P., Engle, D. D., Plenker, D., Deschênes, A., Somerville, T. D. D., Froeling, F. E. M., Burkhart, R. A., Denroche, R. E., Jang, G.-H., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0349 · Cited by 1,092 · see citing works

Targeting TGF-β Signaling in Cancer

Colak, S., & ten Dijke, P. (2017) · Trends in cancer · doi:10.1016/j.trecan.2016.11.008 · Cited by 1,003 · see citing works

Hereditary Pancreatitis and the Risk of Pancreatic Cancer

Lowenfels, A. B., Maisonneuve, P., DiMagno, E. P., Elitsur, Y., Gates, L. K., Perrault, J., Whitcomb, D. C., & International Hereditary Pancreatitis Study Group (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.6.442 · Cited by 988 · see citing works

PARP inhibitor upregulates PD-L1 expression and enhances cancer-associated immunosuppression

Jiao, S., Xia, W., Yamaguchi, H., Wei, Y., Chen, M.-K., Hsu, J.-M., Hsu, J. L., Yu, W.-H., Du, Y., Lee, H.-H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3215 · Cited by 981 · see citing works

A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas

Basturk, O., Hong, S.-M., Wood, L. D., Adsay, N. V., Albores-Saavedra, J., Biankin, A. V., Brosens, L. A. A., Fukushima, N., Goggins, M., Hruban, R. H., et al. (2015) · American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000533 · Cited by 864 · see citing works

Breast-Cancer Risk in Families with Mutations in PALB2

Antoniou, A. C., Casadei, S., Heikkinen, T., Barrowdale, D., Pylkäs, K., Roberts, J., Lee, A., Subramanian, D., Leeneer, K. D., Fostira, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400382 · Cited by 853 · see citing works

Gemcitabine Plus Bevacizumab Compared With Gemcitabine Plus Placebo in Patients With Advanced Pancreatic Cancer: Phase III Trial of the Cancer and Leukemia Group B (CALGB 80303)

Kindler, H. L., Niedzwiecki, D., Hollis, D. R., Sutherland, S., Schrag, D., Hurwitz, H. I., Innocenti, F., Mulcahy, M. F., O'Reilly, E. M., Wozniak, T. F., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.1386 · Cited by 848 · see citing works

Exomic Sequencing Identifies <i>PALB2</i> as a Pancreatic Cancer Susceptibility Gene

Jones, S., Hruban, R. H., Kamiyama, M., Borges, M., Zhang, X., Parsons, D. W., Lin, J. C.-H., Palmisano, E., Brune, K., Jaffee, E. M., et al. (2009) · Science · doi:10.1126/science.1171202 · Cited by 826 · see citing works

Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development

Wu, J., Matthaei, H., Maitra, A., Molin, M. D., Wood, L., Eshleman, J., Goggins, M., Canto, M., Schulick, R., Edil, B., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002543 · Cited by 786 · see citing works

International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer

Canto, M. I., Harinck, F., Hruban, R. H., Offerhaus, G. J., Poley, J.-W., Kamel, I., Nio, Y., Schulick, R. S., Bassi, C., Kluijt, I., et al. (2013) · Gut · doi:10.1136/gutjnl-2012-303108 · Cited by 784 · see citing works

Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia

Kanda, M., Matthaei, H., Wu, J., Hong, S., Yu, J., Borges, M., Hruban, R. H., Maitra, A., Kinzler, K., Vogelstein, B., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.12.042 · Cited by 741 · see citing works

Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer

Amundadottir, L. T., Kraft, P., Stolzenberg‐Solomon, R. Z., Fuchs, C. S., Petersen, G. M., Arslan, A. A., Bueno-de-Mesquita, H. B., Gross, M., Helzlsouer, K. J., Jacobs, E. J., et al. (2009) · Nature Genetics · doi:10.1038/ng.429 · Cited by 705 · see citing works

Tumor-suppressive pathways in pancreatic carcinoma.

Rozenblum, E., Schutte, M. E. M., Goggins, M., Hahn, S. A., Panzer, S., ZAHURAK, M. L., Goodman, S. N., Sohn, T. A., Hruban, R. H., Yeo, C. J., et al. (1997) · PubMed · Cited by 693 · see citing works

The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals

Struewing, J., Abeliovich, D., Peretz, T., Avishai, N., Kaback, M., Collins, F., & Brody, L. (1995) · Nature Genetics · doi:10.1038/ng1095-198 · Cited by 678 · see citing works

K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization.

Hruban, R. H., van Mansfeld, A. D. M., Offerhaus, G. J. A., van Weering, D. H. J., Allison, D. C., Goodman, S. N., Kensler, T. W., Bose, K., Cameron, J. L., & Bos, J. L. (1993) · PubMed Central · Cited by 650 · see citing works

Frequent detection of pancreatic lesions in asymptomatic high-risk individuals

Canto, M. I., Hruban, R. H., Fishman, E. K., Kamel, I. R., Schulick, R., Zhang, Z., Topazian, M., Takahashi, N., Fletcher, J., Petersen, G., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.01.005 · Cited by 648 · see citing works

Whole-exome sequencing of neoplastic cysts of the pancreas reveals recurrent mutations in components of ubiquitin-dependent pathways

Wu, J., Jiao, Y., Molin, M. D., Maitra, A., de Wilde, R. F., Wood, L. D., Eshleman, J. R., Goggins, M., Wolfgang, C. L., Canto, M. I., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1118046108 · Cited by 640 · see citing works

Phase III Study Comparing Gemcitabine Plus Cetuximab Versus Gemcitabine in Patients With Advanced Pancreatic Adenocarcinoma: Southwest Oncology Group–Directed Intergroup Trial S0205

Philip, P. A., Benedetti, J., Corless, C. L., Wong, R., O'Reilly, E. M., Flynn, P. J., Rowland, K. M., Atkins, J. N., Mirtsching, B. C., Rivkin, S. E., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.7550 · Cited by 632 · see citing works

KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas

Smit, V. T. H. B. M., Boot, A. J., de Vries-Smits, A. M. M., Fleuren, G. J., Cornelisse, C. J., & Bos, J. L. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.16.7773 · Cited by 625 · see citing works

Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2–Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO-013/LOGiC—A Randomized Phase III Trial

Hecht, J. R., Bang, Y., Qin, S., Chung, H. C., Xu, J., Park, J. O., Jeziorski, K., Shparyk, Y. V., Hoff, P. M., Sobrero, A. F., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.6598 · Cited by 624 · see citing works

Genomics-driven precision medicine for advanced pancreatic cancer: early results from the COMPASS trial

Aung, K. L., Fischer, S. E., Denroche, R. E., Jang, G.-H., Dodd, A., Creighton, S., Southwood, B., Liang, S.-B., Chadwick, D., Zhang, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2994 · Cited by 618 · see citing works

A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33

Petersen, G. M., Amundadottir, L. T., Fuchs, C. S., Kraft, P., Stolzenberg‐Solomon, R. Z., Jacobs, K. B., Arslan, A. A., Bueno-de-Mesquita, H. B., Gallinger, S., Gross, M. D., et al. (2010) · Nature Genetics · doi:10.1038/ng.522 · Cited by 596 · see citing works

Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression.

Wilentz, R. E., Iacobuzio–Donahue, C. A., Argani, P., McCarthy, D. M., Parsons, J. L., Yeo, C. J., Kern, S. E., & Hruban, R. H. (2000) · PubMed · Cited by 591 · see citing works

Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers

Cohen, J. D., Javed, A. A., Thoburn, C. J., Wong, F., Tie, J., Gibbs, P., Schmidt, C. M., Yip-Schneider, M., Allen, P. J., Schattner, M. A., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1704961114 · Cited by 581 · see citing works

Association Between Inherited Germline Mutations in Cancer Predisposition Genes and Risk of Pancreatic Cancer

Hu, C., Hart, S. N., Polley, E. C., Gnanaolivu, R., Shimelis, H., Lee, K. Y., Lilyquist, J., Na, J., Moore, R., Antwi, S. O., et al. (2018) · JAMA · doi:10.1001/jama.2018.6228 · Cited by 577 · see citing works

Risk of Pancreatic Cancer in Families With Lynch Syndrome

Kastrinos, F. (2009) · JAMA · doi:10.1001/jama.2009.1529 · Cited by 544 · see citing works

A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns

Notta, F., Chan-Seng-Yue, M., Lemire, M., Li, Y., Wilson, G. W., Connor, A. A., Denroche, R. E., Liang, S.-B., Brown, A. M. K., Kim, J. C., et al. (2016) · Nature · doi:10.1038/nature19823 · Cited by 528 · see citing works

FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy

Kim, G. S., Ison, G., McKee, A. E., Zhang, H., Tang, S.-H., Gwise, T., Sridhara, R., Lee, E. Y., Tzou, A., Philip, R., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0887 · Cited by 508 · see citing works

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Tabernero, J. M., Hoff, P. M., Shen, L., Ohtsu, A., Shah, M. A., Cheng, K., Song, C., Wu, H., Eng‐Wong, J., Kim, K. K., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30481-9 · Cited by 496 · see citing works

<i>ATM</i> Mutations in Patients with Hereditary Pancreatic Cancer

Roberts, N. J., Jiao, Y., Yu, J., Kopelovich, L., Petersen, G. M., Bondy, M. L., Gallinger, S., Schwartz, A. G., Syngal, S., Cote, M. L., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0194 · Cited by 491 · see citing works

Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients

Sausen, M., Phallen, J., Adleff, V., Jones, S., Leary, R. J., Barrett, M. T., Anagnostou, V., Parpart-Li, S., Murphy, D., Kay Li, Q., et al. (2015) · Nature Communications · doi:10.1038/ncomms8686 · Cited by 484 · see citing works

A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts

Springer, S., Wang, Y., Dal Molin, M., Masica, D. L., Jiao, Y., Kinde, I., Blackford, A., Raman, S. P., Wolfgang, C. L., Tomita, T., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.07.041 · Cited by 477 · see citing works

Pathologically and Biologically Distinct Types of Epithelium in Intraductal Papillary Mucinous Neoplasms: Delineation of an “Intestinal” Pathway of Carcinogenesis in the Pancreas

Adsay, N., Merati, K., Basturk, O., Iacobuzio-Donahue, C., Levi, E., Cheng, J. D., Sarkar, F. H., Hruban, R., & Klimstra, D. (2004) · American Journal of Surgical Pathology · doi:10.1097/00000478-200407000-00001 · Cited by 460 · see citing works

Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma

Shindo, K., Yu, J., Suenaga, M., Fesharakizadeh, S., Cho, C., Macgregor-Das, A., Siddiqui, A., Witmer, P. D., Tamura, K., Song, T. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.3502 · Cited by 458 · see citing works

p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions.

Redston, M. S., Caldas, C., Seymour, A. B., Hruban, R. H., da Costa, L., Yeo, C. J., & Kern, S. E. (1994) · PubMed · Cited by 451 · see citing works

Whole-exome sequencing uncovers frequent GNAS mutations in intraductal papillary mucinous neoplasms of the pancreas

Furukawa, T., Kuboki, Y., Tanji, E., Yoshida, S., Hatori, T., Yamamoto, M., Shibata, N., Shimizu, K., Kamatani, N., & Shiratori, K. (2011) · Scientific Reports · doi:10.1038/srep00161 · Cited by 442 · see citing works

Cancer risks in BRCA2 families: estimates for sites other than breast and ovary

van Asperen, C. J., Brohet, R. M., Meijers-Heijboer, E. J., Hoogerbrugge, N., Verhoef, S., Vasen, H. F. A., Ausems, M. G. E. M., Menko, F. H., Gómez-García, E. B., Klijn, J. G. M., et al. (2005) · Journal of Medical Genetics · doi:10.1136/jmg.2004.028829 · Cited by 419 · see citing works

Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance

Canto, M. I., Almario, J. A., Schulick, R. D., Yeo, C. J., Klein, A., Blackford, A., Shin, E. J., Sanyal, A., Yenokyan, G., Lennon, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.05.035 · Cited by 414 · see citing works

Preoperative next-generation sequencing of pancreatic cyst fluid is highly accurate in cyst classification and detection of advanced neoplasia

Singhi, A. D., McGrath, K., Brand, R. E., Khalid, A., Zeh, H. J., Chennat, J. S., Fasanella, K. E., Papachristou, G. I., Slivka, A., Bartlett, D. L., et al. (2018) · Gut · doi:10.1136/gutjnl-2016-313586 · Cited by 405 · see citing works

Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer

Makohon-Moore, A. P., Zhang, M., Reiter, J. G., Bozic, I., Allen, B., Kundu, D., Chatterjee, K., Wong, F., Jiao, Y., Kohutek, Z. A., et al. (2017) · Nature Genetics · doi:10.1038/ng.3764 · Cited by 403 · see citing works

Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study

Kindler, H. L., Ioka, T., Richel, D. J., Bennouna, J., Letourneau, R., Okusaka, T., Funakoshi, A., Furuse, J., Park, Y. S., Ohkawa, S., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70004-3 · Cited by 402 · see citing works

ABO Blood Group and the Risk of Pancreatic Cancer

Wolpin, B. M., Chan, A. T., Hartge, P., Chanock, S. J., Kraft, P., Hunter, D. J., Giovannucci, E. L., & Fuchs, C. S. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp020 · Cited by 399 · see citing works

Germline <i>BRCA</i> Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma

Holter, S., Borgida, A., Dodd, A., Grant, R., Semotiuk, K., Hedley, D., Dhani, N., Narod, S., Akbari, M., Moore, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7401 · Cited by 398 · see citing works

K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions.

Pellegata, N. S., Sessa, F., Renault, B., Bonato, M., Leone, B. E., Solcia, E., & Ranzani, G. N. (1994) · PubMed · Cited by 389 · see citing works

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers

Bono, J. S. D., Ramanathan, R. K., Mina, L. A., Chugh, R. K., Glaspy, J. A., Rafii, S., Kaye, S. B., Sachdev, J. C., Heymach, J. V., Smith, D. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1250 · Cited by 385 · see citing works

The carrier frequency of the BRCA2 6174delT mutation among Ashkenazi Jewish individuals is approximately 1%

Oddoux, C., Struewing, J. P., Clayton, C. M., Neuhausen, S. L., Brody, L. C., Kaback, M. M., Haas, B. R., Norton, L., Borgen, P. I., Jhanwar, S. C., et al. (1996) · Nature Genetics · doi:10.1038/ng1096-188 · Cited by 381 · see citing works

Hereditary Colorectal Cancer Syndromes: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the Familial Risk–Colorectal Cancer: European Society for Medical Oncology Clinical Practice Guidelines

Stoffel, E. M., Mangu, P. B., Gruber, S. B., Hamilton, S. R., Kalady, M. F., Lau, M. W. Y., Lu, K. H., Roach, N., & Limburg, P. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1322 · Cited by 374 · see citing works

Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations

Hu, Z. I., Shia, J., Stadler, Z. K., Varghese, A. M., Capanu, M., Salo‐Mullen, E. E., Lowery, M. A., Diaz, L. A., Mandelker, D. L., Yu, K. H., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3099 · Cited by 371 · see citing works

Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine

Aguirre, A. J., Nowak, J. A., Camarda, N. D., Moffitt, R. A., Ghazani, A. A., Hazar-Rethinam, M., Raghavan, S., Kim, J., Brais, L. K., Ragon, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0275 · Cited by 367 · see citing works

Telomere Shortening Is Nearly Universal in Pancreatic Intraepithelial Neoplasia

van Heek, N. T., Meeker, A. K., Kern, S. E., Yeo, C. J., Lillemoe, K. D., Cameron, J. L., Offerhaus, G. J. A., Hicks, J. L., Wilentz, R. E., Goggins, M. G., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)64432-x · Cited by 363 · see citing works

BRCA2 germline mutations in male breast cancer cases and breast cancer families

Couch, F. J., Farid, L. M., DeShano, M. L., Tavtigian, S. V., Calzone, K., Campeau, L., Peng, Y., Bogden, B., Chen, Q., Neuhausen, S. L., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-123 · Cited by 362 · see citing works

Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer

Roberts, N. J., Norris, A. L., Petersen, G. M., Bondy, M. L., Brand, R., Gallinger, S., Kurtz, R. C., Olson, S. H., Rustgi, A. K., Schwartz, A. G., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0402 · Cited by 361 · see citing works

Targeted next‐generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas

Amato, E., Molin, M. D., Mafficini, A., Yu, J. Q., Malleo, G., Rusev, B. C., Fassan, M., Antonello, D., Sadakari, Y., Castelli, P., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4344 · Cited by 349 · see citing works

Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers

Vasen, H., Ibrahim, I., Ponce, C. G., Slater, E. P., Matthäi, E., Carrato, A., Earl, J., Robbers, K., van Mil, A. M., Potjer, T., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0730 · Cited by 344 · see citing works

Frequency of K-ras Mutations in Pancreatic Intraductal Neoplasias Associated with Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis: A Meta-Analysis

Löhr, M., Klöppel, G., Maisonneuve, P., Lowenfels, A. B., & Lüttges, J. (2005) · Neoplasia · doi:10.1593/neo.04445 · Cited by 343 · see citing works

Inactivation of the p16 (INK4A) tumor-suppressor gene in pancreatic duct lesions: loss of intranuclear expression.

Wilentz, R. E., Geradts, J., Maynard, R. D., Offerhaus, G. J. A., Kang, M., Goggins, M., Yeo, C. J., Kern, S. E., & Hruban, R. H. (1998) · PubMed · Cited by 337 · see citing works

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer

Wolpin, B. M., Rizzato, C., Kraft, P., Kooperberg, C. L., Petersen, G. M., Wang, Z., Arslan, A. A., Freeman, L. E. B., Bracci, P. M., Buring, J. E., et al. (2014) · Nature Genetics · doi:10.1038/ng.3052 · Cited by 334 · see citing works

Pancreatic adenocarcinomas frequently show p53 gene mutations.

Scarpa, A., Capelli, P., Mukai, K., Zamboni, G., Oda, T., Iacono, C., & Hirohashi, S. (1993) · PubMed Central · Cited by 332 · see citing works

Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer

Neuhausen, S. L., Gilewski, T. A., Norton, L., Tran, T. D., McGuire, P. J., Swensen, J. J., Hampel, H., Borgen, P. I., Brown, K., Skolnick, M. H., et al. (1996) · Nature Genetics · doi:10.1038/ng0596-126 · Cited by 303 · see citing works

BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study

Zhen, D. B., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Goggins, M. G., Hruban, R. H., Cote, M. L., McWilliams, R. R., Roberts, N. J., et al. (2015) · Genetics in Medicine · doi:10.1038/gim.2014.153 · Cited by 295 · see citing works

The Molecular Balancing Act of p16INK4a in Cancer and Aging

LaPak, K. M., & Burd, C. E. (2013) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-13-0350 · Cited by 294 · see citing works

Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas.

Goggins, M., Shekher, M. C., Turnacioglu, K. K., Yeo, C. J., Hruban, R. H., & Kern, S. E. (1998) · PubMed · Cited by 288 · see citing works

CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer

Higuchi, T., Flies, D. B., Marjon, N. A., Mantia-Smaldone, G. M., Ronner, L., Gimotty, P. A., & Adams, S. F. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0044 · Cited by 286 · see citing works

Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma

Connor, A. A., Denroche, R. E., Jang, G. H., Timms, L. E., Kalimuthu, S. N., Selander, I., McPherson, T. A., Wilson, G. W., Chan‐Seng‐Yue, M., Borozan, I., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3916 · Cited by 285 · see citing works

Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer

Klein, A. P., Wolpin, B. M., Risch, H. A., Stolzenberg-Solomon, R. Z., Mocci, E., Zhang, M., Canzian, F., Childs, E. J., Hoskins, J. W., Jermusyk, A., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02942-5 · Cited by 268 · see citing works

Dpc-4 Protein Is Expressed in Virtually All Human Intraductal Papillary Mucinous Neoplasms of the Pancreas

Iacobuzio–Donahue, C. A., Klimstra, D. S., Adsay, V. N., Wilentz, R. E., Argani, P., Sohn, T. A., Yeo, C. J., Cameron, J. L., Kern, S. E., & Hruban, R. H. (2000) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64589-0 · Cited by 256 · see citing works

Pancreatic Cancer Risk and ABO Blood Group Alleles: Results from the Pancreatic Cancer Cohort Consortium

Wolpin, B. M., Kraft, P., Gross, M. D., Helzlsouer, K. J., Bueno-de-Mesquita, H. B., Steplowski, E., Stolzenberg‐Solomon, R. Z., Arslan, A. A., Jacobs, E. J., LaCroix, A. Z., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2993 · Cited by 252 · see citing works

Molecular Profiling of Patients with Pancreatic Cancer: Initial Results from the Know Your Tumor Initiative

Pishvaian, M. J., Bender, R. J., Halverson, D., Rahib, L., Hendifar, A. E., Mikhail, S., Chung, V., Picozzi, V. J., Sohal, D., Blais, E. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0531 · Cited by 245 · see citing works

Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study

Lee, J.-M., Cimino‐Mathews, A., Peer, C. J., Zimmer, A. S., Lipkowitz, S., Annunziata, C. M., Cao, L., Harrell, M. I., Swisher, E. M., Houston, N. D., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1340 · Cited by 243 · see citing works

Allelic Loss Is Often the First Hit in the Biallelic Inactivation of the p53 and DPC4 Genes During Pancreatic Carcinogenesis

Luettges, J., Galehdari, H., Bröcker, V., Schwarte‐Waldhoff, I., Henne‐Bruns, D., Klöppel, G., Schmiegel, W., & Hahn, S. A. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)64123-5 · Cited by 241 · see citing works

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer

Heining, C., Horak, P., Uhrig, S., Codó, P., Klink, B., Hutter, B., Fröhlich, M., Bonekamp, D., Richter, D., Steiger, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0036 · Cited by 240 · see citing works

American Society of Clinical Oncology Expert Statement: Collection and Use of a Cancer Family History for Oncology Providers

Lu, K. H., Wood, M. E., Daniels, M. S., Burke, C., Ford, J. M., Kauff, N. D., Kohlmann, W. K., Lindor, N. M., Mulvey, T. M., Robinson, L. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.9257 · Cited by 238 · see citing works

Genetic susceptibility to pancreatic cancer

Klein, A. P. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20855 · Cited by 235 · see citing works

Genome‐wide DNA methylation patterns in pancreatic ductal adenocarcinoma reveal epigenetic deregulation of SLIT‐ROBO, ITGA2 and MET signaling

Nones, K., Waddell, N., Song, S., Patch, A., Miller, D. K., Johns, A. L., Wu, J., Kassahn, K. S., Wood, D., Bailey, P. J., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28765 · Cited by 229 · see citing works

Aberrant Methylation of Preproenkephalin and p16 Genes in Pancreatic Intraepithelial Neoplasia and Pancreatic Ductal Adenocarcinoma

Fukushima, N., Sato, N., Ueki, T., Rosty, C., Walter, K., Wilentz, R. E., Yeo, C. J., Hruban, R. H., & Goggins, M. (2002) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61104-2 · Cited by 225 · see citing works

Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients

Özcelik, H., Schmocker, B., Nicola, N. D., Shi, X.-H., Langer, B., Moore, M. J., Taylor, B., Narod, S. A., Darlington, G., Andrulis, I. L., et al. (1997) · Nature Genetics · doi:10.1038/ng0597-17 · Cited by 225 · see citing works

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms

Lowery, M. A., Wong, W., Jordan, E. J., Lee, J. W., Kemel, Y., Vijai, J., Mandelker, D., Zehir, A., Capanu, M., Salo-Mullen, E., et al. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djy024 · Cited by 224 · see citing works

Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer

Yurgelun, M. B., Chittenden, A. B., Morales-Oyarvide, V., Rubinson, D. A., Dunne, R. F., Kozak, M. M., Qian, Z. R., Welch, M. W., Brais, L. K., Da Silva, A., et al. (2019) · Genetics in Medicine · doi:10.1038/s41436-018-0009-5 · Cited by 217 · see citing works

Hypermutation In Pancreatic Cancer

Humphris, J. L., Patch, A., Nones, K., Bailey, P. J., Johns, A. L., McKay, S., Chang, D. K.-F., Miller, D. K., Pajic, M., Kassahn, K. S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.09.060 · Cited by 209 · see citing works

BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma

Ferrone, C. R., Levine, D. A., Tang, L. H., Allen, P. J., Jarnagin, W. R., Brennan, M. F., Offit, K., & Robson, M. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.5546 · Cited by 206 · see citing works

Cell cycle activation by c-myc in a Burkitt lymphoma model cell line

Pajic, A., Spitkovsky, D., Christoph, B., Kempkes, B., Schuhmacher, M., Staege, M. S., Brielmeier, M., Ellwart, J. W., Kohlhuber, F., Bornkamm, G. W., et al. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000915)87:6 · Cited by 204 · see citing works

Current progress in immunotherapy for pancreatic cancer

Foley, K., Kim, V., Jaffee, E. M., & Zheng, L. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.12.020 · Cited by 202 · see citing works

Genetic Alterations Associated With Progression From Pancreatic Intraepithelial Neoplasia to Invasive Pancreatic Tumor

Murphy, S. J., Hart, S. N., Lima, J. F., Kipp, B. R., Klebig, M. L., Winters, J. L., Szabo, C., Zhang, L., Eckloff, B. W., Petersen, G. M., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.07.049 · Cited by 199 · see citing works

Identification of germline genetic mutations in patients with pancreatic cancer

Salo‐Mullen, E. E., O'Reilly, E. M., Kelsen, D. P., Ashraf, A. M., Lowery, M. A., Yu, K. H., Reidy‐Lagunes, D. L., Epstein, A. S., Lincoln, A., Saldia, A., et al. (2015) · Cancer · doi:10.1002/cncr.29664 · Cited by 198 · see citing works

Aberrant p16INK4A and DPC4/Smad4 expression in intraductal papillary mucinous tumours of the pancreas is associated with invasive ductal adenocarcinoma

Biankin, A. V., Biankin, S. A., Kench, J. G., Morey, A. L., Lee, C.-S., Head, D. R., Eckstein, R. P., Hugh, T. B., Henshall, S. M., & Sutherland, R. L. (2002) · Gut · doi:10.1136/gut.50.6.861 · Cited by 186 · see citing works

Randomised, placebo-controlled, double-blind, parallel-group phase III study evaluating aflibercept in patients receiving first-line treatment with gemcitabine for metastatic pancreatic cancer

Rougier, P. R., Riess, H. B., Manges, R., Karásek, P., Humblet, Y., Barone, C., Santoro, A., Assadourian, S., Hatteville, L., & Philip, P. A. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.04.002 · Cited by 184 · see citing works

Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial

Manchanda, R., Loggenberg, K., Sanderson, S. C., Burnell, M., Wardle, J., Gessler, S., Side, L. E., Balogun, N., Desai, R., Kumar, A., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju379 · Cited by 183 · see citing works

Sequential Accumulation of K-ras Mutations and p53 Overexpression in the Progression of Pancreatic Mucinous Cystic Neoplasms to Malignancy

Jimenez, R. E., Warshaw, A. L., Z’graggen, K., Hartwig, W., Taylor, D. Z., Compton, C. C., & Castillo, C. F.-D. (1999) · Annals of Surgery · doi:10.1097/00000658-199910000-00006 · Cited by 180 · see citing works

Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma

Vincent, A., Omura, N., Hong, S., Jaffe, A. E., Eshleman, J. R., & Goggins, M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3431 · Cited by 177 · see citing works

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

Shroff, R. T., Hendifar, A. E., McWilliams, R. R., Geva, R., Epelbaum, R., Rolfe, L., Goble, S. M., Lin, K., Biankin, A. V., Giordano, H., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00316 · Cited by 175 · see citing works

Mutant GNAS detected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts

Kanda, M., Knight, S., Topazian, M. D., Syngal, S., Farrell, J. J., Lee, J. D., Kamel, I. R., Lennon, A. M., Borges, M. W., Young, A., et al. (2012) · Gut · doi:10.1136/gutjnl-2012-302823 · Cited by 170 · see citing works

A phase 3 randomized, double-blind, placebo-controlled trial of ganitumab or placebo in combination with gemcitabine as first-line therapy for metastatic adenocarcinoma of the pancreas: the GAMMA trial

Fuchs, C. S., Azevedo, S. J., Okusaka, T., Laethem, J. V., Lipton, L. R., Riess, H. B., Szczylik, C. A., Moore, M. J., Peeters, M., Bodoky, G., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv027 · Cited by 168 · see citing works

Dpc4 Protein in Mucinous Cystic Neoplasms of the Pancreas

Iacobuzio–Donahue, C. A., Wilentz, R. E., Argani, P., Yeo, C. J., Cameron, J. L., Kern, S. E., & Hruban, R. H. (2000) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200011000-00011 · Cited by 166 · see citing works

PIK3CA Mutations in Intraductal Papillary Mucinous Neoplasm/Carcinoma of the Pancreas

Schönleben, F., Qiu, W., Ciau, N. T., Ho, D. J., Li, X., Allendorf, J., Remotti, H. E., & Su, G. H. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0292 · Cited by 164 · see citing works

Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms

Yu, J., Sadakari, Y., Shindo, K., Suenaga, M., Brant, A., Almario, J. A. N., Borges, M., Barkley, T., Fesharakizadeh, S., Ford, M., et al. (2017) · Gut · doi:10.1136/gutjnl-2015-311166 · Cited by 164 · see citing works

Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma

Safran, H. P., Steinhoff, M. M., Mangray, S., Rathore, R., King, T. C., Chai, L., Berzein, K., Moore, T. T., Iannitti, D. A., Reiss, P. T., et al. (2001) · American Journal of Clinical Oncology · doi:10.1097/00000421-200110000-00016 · Cited by 162 · see citing works

Genetic analyses of isolated high‐grade pancreatic intraepithelial neoplasia (HG‐PanIN) reveal paucity of alterations in TP53 and SMAD4

Hosoda, W., Chianchiano, P. E., Griffin, J. F., Pittman, M. E., Brosens, L. A. A., Noë, M., Yu, J., Shindo, K., Suenaga, M., Rezaee, N., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4884 · Cited by 158 · see citing works

Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma

Lowery, M. A., Kelsen, D. P., Capanu, M., Smith, S., Lee, J. W., Stadler, Z. K., Moore, M. J., Kindler, H. L., Golan, T., Segal, A., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.11.004 · Cited by 156 · see citing works

Absence of E-Cadherin Expression Distinguishes Noncohesive from Cohesive Pancreatic Cancer

Winter, J. M., Ting, A. H., Vilardell, F., Gallmeier, E., Baylin, S. B., Hruban, R. H., Kern, S. E., & Iacobuzio–Donahue, C. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0487 · Cited by 153 · see citing works

IPMNs with co-occurring invasive cancers: neighbours but not always relatives

Felsenstein, M., Noë, M., Masica, D. L., Hosoda, W., Chianchiano, P. E., Fischer, C. G., Lionheart, G., Brosens, L. A. A., Pea, A., Yu, J., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-315062 · Cited by 145 · see citing works

Prevalence of pathogenic mutations in cancer predisposition genes among pancreatic cancer patients

Hu, C., Hart, S. N., Bamlet, W. R., Moore, R. M., Nandakumar, K., Eckloff, B. W., Lee, Y. K., Petersen, G. M., McWilliams, R. R., & Couch, F. J. (2016) · Cancer Epidemiology, Biomarkers &amp; Prevention · doi:10.1158/1055-9965.epi-15-0455 · Cited by 137 · see citing works

Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas

Pea, A., Yu, J., Rezaee, N., Luchini, C., He, J. P., Molin, M. D., Griffin, J. F., Fedor, H. L., Fesharakizadeh, S., Salvia, R., et al. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001817 · Cited by 132 · see citing works

Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation Carriers

Metcalfe, K. A., Lynch, H. T., Foulkes, W. D., Tung, N., Kim‐Sing, C., Olopade, O. I., Eisen, A. F., Rosen, B. P., Snyder, C., Gershman, S., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.0658 · Cited by 131 · see citing works

A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer

O’Neil, B. H., Scott, A. J., Ma, W. W., Cohen, S. J., Aisner, D. L., Menter, A. R., Tejani, M. A., Cho, J. K., Granfortuna, J. M., Coveler, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv264 · Cited by 130 · see citing works

Oncogenic Ras Isoforms Signaling Specificity at the Membrane

Nussinov, R., Tsai, C., & Jang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 122 · see citing works

Precancerous neoplastic cells can move through the pancreatic ductal system

Makohon-Moore, A. P., Matsukuma, K., Zhang, M., Reiter, J. G., Gerold, J. M., Jiao, Y., Sikkema, L., Attiyeh, M. A., Yachida, S., Sandone, C., et al. (2018) · Nature · doi:10.1038/s41586-018-0481-8 · Cited by 120 · see citing works

Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine

Knudsen, E. S., O'Reilly, E. M., Brody, J. R., & Witkiewicz, A. K. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.08.056 · Cited by 108 · see citing works

The oncocytic subtype is genetically distinct from other pancreatic intraductal papillary mucinous neoplasm subtypes

Baştürk, O., Tan, M. C. B., Bhanot, U. K., Allen, P. J., Adsay, V. N., Scott, S. N., Shah, R. H., Berger, M. F., Askan, G., Dikoglu, E., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.98 · Cited by 107 · see citing works

Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild‐type BRCA pancreatic ductal adenocarcinoma

O'Reilly, E. M., Lee, J. W., Lowery, M. A., Capanu, M., Stadler, Z. K., Moore, M. J., Dhani, N. C., Kindler, H. L., Estrella, H., Maynard, H., et al. (2018) · Cancer · doi:10.1002/cncr.31218 · Cited by 103 · see citing works

A randomized, placebo-controlled phase III trial of masitinib plus gemcitabine in the treatment of advanced pancreatic cancer

Deplanque, G., Demarchi, M., Hebbar, M., Flynn, P. J., Melichar, B., Atkins, J., Nowara, E., Moyé, L. A., Piquemal, D., Ritter, D., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv133 · Cited by 97 · see citing works

Risk of Pancreatic Cancer in Breast Cancer Families from the Breast Cancer Family Registry

Mocci, E., Milne, R. L., Méndez-Villamil, E. Y., Hopper, J. L., John, E. M., Andrulis, I. L., Chung, W. K., Daly, M. B., Buys, S. S., Malats, N., et al. (2013) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-12-0195 · Cited by 97 · see citing works

Somatic Mutations in PIK3CA and Activation of AKT in Intraductal Tubulopapillary Neoplasms of the Pancreas

Yamaguchi, H., Kuboki, Y., Hatori, T., Yamamoto, M., Shiratori, K., Kawamura, S., Kobayashi, M., Shimizu, M., Ban, S., Koyama, I., et al. (2011) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31822769a0 · Cited by 96 · see citing works

Mutations in the pancreatic secretory enzymes <i>CPA1</i> and <i>CPB1</i> are associated with pancreatic cancer

Tamura, K., Yu, J., Hata, T., Suenaga, M., Shindo, K., Abe, T., MacGregor-Das, A., Borges, M., Wolfgang, C. L., Weiss, M. J., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720588115 · Cited by 95 · see citing works

Variant ABO Blood Group Alleles, Secretor Status, and Risk of Pancreatic Cancer: Results from the Pancreatic Cancer Cohort Consortium

Wolpin, B. M., Kraft, P., Xu, M., Steplowski, E., Olsson, M. L., Arslan, A. A., Bueno-de-Mesquita, H. B., Gross, M. D., Helzlsouer, K. J., Jacobs, E. J., et al. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0751 · Cited by 90 · see citing works

Prospective study of germline genetic testing in incident cases of pancreatic adenocarcinoma

Brand, R. E., Borazanci, E. H., Speare, V., Dudley, B., Karloski, E., Peters, M. L. B., Stobie, L., Bahary, N., Zeh, H. J., Zureikat, A. H., et al. (2018) · Cancer · doi:10.1002/cncr.31628 · Cited by 88 · see citing works

Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer

Golan, T., Sella, T., O'Reilly, E. M., Katz, M. H. G., Epelbaum, R., Kelsen, D. P., Borgida, A., Maynard, H., Kindler, H. L., Friedmen, E., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.19 · Cited by 86 · see citing works

KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound

Eshleman, J. R., Norris, A. L., Sadakari, Y., Debeljak, M., Borges, M. W., Harrington, C. T., Lin, E. I., Brant, A., Barkley, T., Almario, J. A., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.11.028 · Cited by 82 · see citing works

Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance

Suenaga, M., Yu, J., Shindo, K., Tamura, K., Almario, J. A., Zaykoski, C., Witmer, P. D., Fesharakizadeh, S., Borges, M., Lennon, A.-M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2463 · Cited by 81 · see citing works

Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer

Yarchoan, M. M., Myzak, M. C., Johnson, B. A., Jesus‐Acosta, A. D., Le, D. T., Jaffee, E. M., Azad, N. S., Donehower, R. C., Zheng, L., Oberstein, P. E., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17237 · Cited by 77 · see citing works

Predicting the Grade of Dysplasia of Pancreatic Cystic Neoplasms Using Cyst Fluid DNA Methylation Markers

Hata, T., Molin, M. D., Hong, S., Tamura, K., Suenaga, M., Yu, J., Sedogawa, H., Weiss, M. J., Wolfgang, C. L., Lennon, A. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2244 · Cited by 74 · see citing works

Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer

Kondo, T., Kanai, M., Kou, T., Sakuma, T., Mochizuki, H., Kamada, M., Nakatsui, M., Uza, N., Kodama, Y., Masui, T., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24865 · Cited by 72 · see citing works

<i>BRCA1</i> and <i>BRCA2</i> germline mutations are frequently demonstrated in both high‐risk pancreatic cancer screening and pancreatic cancer cohorts

Lucas, A. L., Frado, L. E., Hwang, C., Kumar, S., Khanna, L. G., Levinson, E. J., Chabot, J. A., Chung, W. K., & Frucht, H. (2014) · Cancer · doi:10.1002/cncr.28662 · Cited by 68 · see citing works

Single‐cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions

Kuboki, Y., Fischer, C. G., Guthrie, V. B., Huang, W., Yu, J., Chianchiano, P. E., Hosoda, W., Zhang, H., Zheng, L., Shao, X. M., et al. (2018) · The Journal of Pathology · doi:10.1002/path.5194 · Cited by 62 · see citing works

Highly Accurate Identification of Cystic Precursor Lesions of Pancreatic Cancer Through Targeted Mass Spectrometry: A Phase IIc Diagnostic Study

Jabbar, K. S., Arike, L., Verbeke, C. S., Sadik, R., & Hansson, G. C. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7288 · Cited by 62 · see citing works

Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer

Hong, S., Vincent, A., Kanda, M., Leclerc, J., Omura, N., Borges, M. W., Klein, A. P., Canto, M. I., Hruban, R. H., & Goggins, M. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1075 · Cited by 59 · see citing works

Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations

Reiss, K. A., Yu, S., Judy, R., Symecko, H., Nathanson, K. L., & Domchek, S. M. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00152 · Cited by 59 · see citing works

Multigene Hereditary Cancer Panels Reveal High-Risk Pancreatic Cancer Susceptibility Genes

Hu, C., LaDuca, H., Shimelis, H., Polley, E. C., Lilyquist, J., Hart, S. N., Na, J., Thomas, A., Lee, K. Y., Davis, B. T., et al. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00291 · Cited by 58 · see citing works

The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel

Figer, A., Irmin, L., Geva, R., Flex, D., Sulkes, J., Sulkes, A., & Friedman, E. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1605 · Cited by 57 · see citing works

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials

Ottaiano, A., Capozzi, M., Divitiis, C. D., Stefano, A. D., Botti, G., Avallone, A., & Tafuto, S. (2017) · Acta Oncologica · doi:10.1080/0284186x.2017.1288922 · Cited by 53 · see citing works

Cyst Fluid Telomerase Activity Predicts the Histologic Grade of Cystic Neoplasms of the Pancreas

Hata, T., Molin, M. D., Suenaga, M., Yu, J., Pittman, M. E., Weiss, M. J., Canto, M. I., Wolfgang, C. L., Lennon, A. M., Hruban, R. H., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0311 · Cited by 50 · see citing works

Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review

Sheahan, A. V., Biankin, A. V., Parish, C. R., & Khachigian, L. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25085 · Cited by 49 · see citing works

Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia

Hata, T., Suenaga, M., Marchionni, L., Macgregor-Das, A. M., Yu, J., Shindo, K., Tamura, K., Hruban, R. H., & Goggins, M. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.03.012 · Cited by 48 · see citing works

Cancerization of the Pancreatic Ducts

Hutchings, D., Waters, K. M., Weiss, M. J., Wolfgang, C. L., Makary, M. A., He, J. P., Cameron, J. L., Wood, L. D., & Hruban, R. H. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001148 · Cited by 47 · see citing works

Aberrant methylation of Reprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma

Sato, N., Fukushima, N., Matsubayashi, H., Iacobuzio–Donahue, C. A., Yeo, C. J., & Goggins, M. (2006) · Cancer · doi:10.1002/cncr.21977 · Cited by 46 · see citing works

Genomic Characterization of Low- and High-Grade Pancreatic Mucinous Cystic Neoplasms Reveals Recurrent KRAS Alterations in “High-Risk” Lesions

Conner, J., Mariño‐Enríquez, A., Mino-Kenudson, M. A., Garcia, E. P., Pitman, M. B., Sholl, L. M., Srivastava, A., & Doyle, L. A. (2017) · Pancreas · doi:10.1097/mpa.0000000000000805 · Cited by 40 · see citing works

Factors associated with cancer worries in individuals participating in annual pancreatic cancer surveillance

Konings, I. C. A. W., Harinck, F., Kuenen, M. A., Sidharta, G. N., Kieffer, J. M., Aalfs, C. M., Poley, J., Smets, E. M. A., Wagner, A., van Rens, A., et al. (2016) · Familial Cancer · doi:10.1007/s10689-016-9930-4 · Cited by 39 · see citing works

Germline mutation prevalence in individuals with pancreatic cancer and a history of previous malignancy

Dudley, B., Karloski, E., Monzon, F. A., Singhi, A. D., Lincoln, S. E., Bahary, N., & Brand, R. E. (2018) · Cancer · doi:10.1002/cncr.31242 · Cited by 37 · see citing works

Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study

Childs, E. J., Rabe, K. G., Gallinger, S., Syngal, S., Schwartz, A. G., Coté, M. L., Bondy, M. L., Hruban, R. H., Chanock, S. J., Hoover, R. N., et al. (2016) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-1217 · Cited by 34 · see citing works

Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy

Shahda, S., Timms, K. M., Ibrahim, A., Reid, J., Cramer, H. M., Radovich, M., Ibrahim, S., Allen, B. A., & O’Neil, B. H. (2018) · JCO Precision Oncology · doi:10.1200/po.17.00087 · Cited by 22 · see citing works

Early Detection of Pancreatic Cancer: Opportunities and Challenges

Singhi, A. D., Koay, E. J., Chari, S. T., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.259 · Cited by 841 · see citing works

Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium

Goggins, M., Overbeek, K. A., Brand, R., Syngal, S., Del Chiaro, M., Bartsch, D. K., Bassi, C., Carrato, A., Farrell, J., Fishman, E. K., et al. (2020) · Gut · doi:10.1136/gutjnl-2019-319352 · Cited by 659 · see citing works

Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention

Stoffel, E. M., Brand, R. E., & Goggins, M. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.012 · Cited by 540 · see citing works

Burden of Pancreatic Cancer: From Epidemiology to Practice

Khalaf, N., El-Serag, H. B., Abrams, H. R., & Thrift, A. P. (2021) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.02.054 · Cited by 308 · see citing works

A faecal microbiota signature with high specificity for pancreatic cancer

Kartal, E., Schmidt, T. S. B., Molina-Montes, E., Rodríguez-Perales, S., Wirbel, J., Maistrenko, O. M., Akanni, W. A., Alashkar Alhamwe, B., Alves, R. J., Carrato, A., et al. (2022) · Gut · doi:10.1136/gutjnl-2021-324755 · Cited by 290 · see citing works

Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis

Blackford, A. L., Canto, M. I., Klein, A. P., Hruban, R. H., & Goggins, M. (2020) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djaa004 · Cited by 270 · see citing works

Pathogenesis and Treatment of Pancreatic Cancer Related Pain

Lohse, I., & Brothers, S. P. (2020) · Anticancer Research · doi:10.21873/anticanres.14133 · Cited by 92 · see citing works

Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer

Hu, Y., & Guo, M. (2020) · Cancer Science · doi:10.1111/cas.14565 · Cited by 78 · see citing works

Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes

Mizukami, K., Iwasaki, Y., Kawakami, E., Hirata, M., Kamatani, Y., Matsuda, K., Endo, M., Sugano, K., Yoshida, T., Murakami, Y., et al. (2020) · EBioMedicine · doi:10.1016/j.ebiom.2020.103033 · Cited by 78 · see citing works

Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma

Nakaoka, K., Ohno, E., Kawabe, N., Kuzuya, T., Funasaka, K., Nakagawa, Y., Nagasaka, M., Ishikawa, T., Watanabe, A., Tochio, T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13020215 · Cited by 53 · see citing works

Pancreatitis and Pancreatic Cancer

Saluja, A. K., & Maitra, A. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.03.050 · Cited by 52 · see citing works

Clostridium butyricum and its metabolite butyrate promote ferroptosis susceptibility in pancreatic ductal adenocarcinoma

Yang, X., Zhang, Z., Shen, X., Xu, J., Weng, Y., Wang, W., & Xue, J. (2023) · Cellular Oncology · doi:10.1007/s13402-023-00831-8 · Cited by 52 · see citing works

HMGA1 induces FGF19 to drive pancreatic carcinogenesis and stroma formation

Chia, L., Wang, B., Kim, J., Luo, L., Shuai, S., Herrera, I., Chen, S. Y., Li, L., Xian, L., Huso, T. H., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci151601 · Cited by 50 · see citing works

Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies

Rozengurt, E., & Eibl, G. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02499-y · Cited by 45 · see citing works

Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy

Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42 · see citing works

CircRNA_000864 Upregulates B-cell Translocation Gene 2 Expression and Represses Migration and Invasion in Pancreatic Cancer Cells by Binding to miR-361-3p

Huang, L., Han, J., Yu, H., Liu, J., Gui, L., Wu, Z., Zhao, X., Su, S., Fu, G., & Li, F. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.547942 · Cited by 30 · see citing works

Emerging role of pancreatic stellate cell-derived extracellular vesicles in pancreatic cancer

Sarkar, R., Xu, Z., Perera, C. J., & Apte, M. V. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.05.007 · Cited by 28 · see citing works

S3-Leitlinie zum exokrinen Pankreaskarzinom – Langversion 2.0 – Dezember 2021 – AWMF-Registernummer: 032/010OL

Seufferlein, T. T. W., Mayerle, J. V., Böck, S., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1856-7346 · Cited by 27 · see citing works

Can Nimesulide Nanoparticles Be a Therapeutic Strategy for the Inhibition of the KRAS/PTEN Signaling Pathway in Pancreatic Cancer?

Ferreira, R. G., Narvaez, L. E. M., Espíndola, K. M. M., Rosario, A. C. R. S., Lima, W. G. N., & Monteiro, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.594917 · Cited by 12 · see citing works

Trap and kill strategy for non-BRCA mutant pancreatic cancer by co-delivery of olaparib and JQ1 with plectin-1 targeting peptide nanoparticles

Wang, Y., Du, C., Zhao, Y., Nie, G., & Yang, Y. (2020) · Nano Today · doi:10.1016/j.nantod.2020.100877 · Cited by 25 · see citing works

Advances for Managing Pancreatic Cystic Lesions: Integrating Imaging and AI Innovations

Seyithanoğlu, D., Durak, G., Keleş, E., Medetalibeyoğlu, A., Hong, Z., Zhang, Z., Taktak, Y. B., Cebeci, T., Tiwari, P., Velichko, Y., et al. (2024) · Cancers · doi:10.3390/cancers16244268 · Cited by 23 · see citing works

Alteration of Epigenetic Modifiers in Pancreatic Cancer and Its Clinical Implication

Hung, Y.-H., Hsu, M.-C., Chen, L.-T., Hung, W., & Pan, M.-R. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8060903 · Cited by 22 · see citing works

Familial Pancreatic Cancer

Saba, H., & Goggins, M. (2022) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2022.06.006 · Cited by 20 · see citing works

Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance

Katona, B. W., Klute, K. A., Brand, R. E., Everett, J. N., Farrell, J. J., Hawthorne, K. M., Kaul, V., Kupfer, S. S., Paiella, S., Simeone, D. M., et al. (2023) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-22-0529 · Cited by 20 · see citing works

Valosin-Containing Protein Stabilizes Mutant p53 to Promote Pancreatic Cancer Growth

Wang, J., Chen, Y., Huang, C., Hao, Q., Zeng, S. X., Omari, S., Zhang, Y., Zhou, X. Y., & Lu, H. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3855 · Cited by 19 · see citing works

A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers

Alruwaili, M., Zonneville, J., Naranjo, M. N., Serio, H., Melendy, T., Straubinger, R. M., Gillard, B. M., Foster, B. A., Rajan, P., Attwood, K. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101434 · Cited by 18 · see citing works

Durable benefit from immunotherapy and accompanied lupus erythematosus in pancreatic adenocarcinoma with DNA repair deficiency

Pang, X., Qian, J., Jin, H., Zhang, L., Lin, L., Wang, Y., Lei, Y., Zhou, Z., Li, M., & Zhang, H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000463 · Cited by 15 · see citing works

Genetic and other risk factors for pancreatic ductal adenocarcinoma (PDAC)

Jacobs, M. F., & Stoffel, E. M. (2024) · Familial Cancer · doi:10.1007/s10689-024-00372-5 · Cited by 12 · see citing works

From classical approaches to artificial intelligence, old and new tools for PDAC risk stratification and prediction

Farinella, R., Felici, A., Peduzzi, G., Testoni, S. G. G., Costello, E., Aretini, P., Blázquez‐Encinas, R., Oz, E., Pastore, A., Tacelli, M., et al. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.03.004 · Cited by 13 · see citing works

Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma

Hu, H., Zhu, Y., Pu, N., Burkhart, R. A., Burns, W. R., Laheru, D. A., Zheng, L., He, J. P., Goggins, M., & Yu, J. (2020) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2020.06.019 · Cited by 12 · see citing works

Pancreatic Cancer: Epidemiology, Risk Factors, and Prevention

Mack, S., Koessler, T., Bichard, P., & Frossard, J. (2025) · Onco · doi:10.3390/onco5030037 · Cited by 11 · see citing works

Pancreatic Cancer

Mohamed, G., Munir, M., Rai, A., & Gaddam, S. (2024) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2024.09.006 · Cited by 10 · see citing works

EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer

Katona, B. W., Long, J. M., Ahmad, N. A., Attalla, S., Bradbury, A. R., Carpenter, E. L., Clark, D. F., Constantino, G., Das, K. K., Domchek, S. M., et al. (2021) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-21-0161 · Cited by 10 · see citing works

Characterization of DNA damage response deficiency in pancreatic cancer patients from China

Zhang, X., Mao, T., Zhang, B., Xu, H., Cui, J., Jiao, F., Chen, D., Wang, Y., Hu, J., Xia, Q., et al. (2021) · 癌症：英文版 · doi:10.1002/cac2.12238 · Cited by 10 · see citing works

Exploring the Common Mutational Landscape in Cutaneous Melanoma and Pancreatic Cancer

Broseghini, E., Venturi, F., Veronesi, G., Scotti, B., Migliori, M., Marini, D., Ricci, C., Casadei, R., Ferracin, M., & Dika, E. (2024) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.13210 · Cited by 9 · see citing works

Germline Pathogenic Variants in Patients with Pancreatic Ductal Adenocarcinoma and Extra-Pancreatic Malignancies: A Nationwide Database Analysis

Kryklyva, V., Pflüger, M. J., Ouchene, H., Volleberg-Gorissen, H., Mensenkamp, A. R., Jonker, M. A., van de Water, C., Nagtegaal, I. D., Ligtenberg, M. J. L., & Brosens, L. A. A. (2025) · Modern Pathology · doi:10.1016/j.modpat.2025.100709 · Cited by 8 · see citing works

S3-Leitlinie Exokrines Pankreaskarzinom – Version 3.1

Seufferlein, T. T. W., Mayerle, J. V., Boeck, S. H., Brunner, T. B., Ettrich, T. J., Grenacher, L., Gress, T. M., Hackert, T., Heinemann, V., Kestler, A. M. R., et al. (2024) · Zeitschrift für Gastroenterologie · doi:10.1055/a-2338-3533 · Cited by 7 · see citing works

The road to overcome pancreatic cancer: Where are we?

Tirpe, A., Streianu, C., Isachesku, E., Şimon, I., & Berindan‐Neagoe, I. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38196 · Cited by 6 · see citing works

Pancreatic duct ligation reduces premalignant pancreatic lesions in a Kras model of pancreatic adenocarcinoma in mice

Cáceres, M., Quesada, R., Iglesias, M., Real, F. X., Villamonte, M., de Villarreal, J. M., Pérez, M., Andaluz, A., Moll, X., BERJANO, E. J., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-74947-4 · Cited by 6 · see citing works

A mathematical model for pancreatic cancer during intraepithelial neoplasia

Briones-Andrade, J., Ramı́rez-Santiago, G., & Romero-Arias, J. R. (2024) · Royal Society Open Science · doi:10.1098/rsos.240702 · Cited by 5 · see citing works

Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

Tavano, F., Gioffreda, D., Fontana, A., Palmieri, O., Gentile, A., Latiano, T. P., Latiano, A., Latiano, T. P., Scaramuzzi, M., Maiello, E., et al. (2023) · Molecular Medicine · doi:10.1186/s10020-023-00600-1 · Cited by 5 · see citing works

DDIT4 Novel Mutations in Pancreatic Cancer

Ding, F., Hong, X., Fan, X., Huang, S., Lian, W., Chen, X., Liu, Q., Chen, Y., & Gao, F. (2021) · Gastroenterology Research and Practice · doi:10.1155/2021/6674404 · Cited by 5 · see citing works

Integrated periodontal pathogens and circulating miRNAs: a novel non-invasive panel of biomarkers for pancreatic cancer

Hesami, Z., Pazienza, V., Olfatifar, M., Sadeghi, A., Mohammadi‐Yeganeh, S., Trivieri, N., Eghlimi, H., Hakemi-Vala, M., Binda, E., & Houri, H. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1678114 · Cited by 4 · see citing works

TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of olaparib and AZD6738 in PDAC

Tang, X.-M., Shi, M.-M., Wang, J., Gu, Y., Dai, Y.-T., Yang, Q.-X., Liu, J., Ren, L., Liu, X.-Y., Yang, C., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01350-9 · Cited by 3 · see citing works

Methylthioadenosine Phosphorylase (MTAP) and p16 Expression in Melanocytic Nevi and Melanoma with Molecular Correlation

He, L., Hornick, J. L., & Russell-Goldman, E. E. (2025) · American Journal of Dermatopathology · doi:10.1097/dad.0000000000003139 · Cited by 3 · see citing works

Implications of Multigene Panel Testing on Psychosocial Outcomes: A Comparison of Patients With Pancreatic and Breast or Ovarian Cancer

Koptiuch, C., Espinel, W., Kohlmann, W. K., Zhao, J., & Kaphingst, K. A. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00199 · Cited by 3 · see citing works

Investigating the interference of single nucleotide polymorphisms with miRNA mediated gene regulation in pancreatic ductal adenocarcinoma: An in silico approach

Mukherjee, M., Ghosh, S., & Goswami, S. (2022) · Gene · doi:10.1016/j.gene.2022.146259 · Cited by 3 · see citing works

Germline sequence analysis of RABL3 in a large series of pancreatic ductal adenocarcinoma patients reveals no evidence of deleterious variants

Roberts, N. J., Grant, R. C., Gallinger, S., Klein, A. P., & the Familial Pancreatic Cancer Genome Sequencing Project (2021) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22947 · Cited by 3 · see citing works

Blockade of CC chemokine receptor 2 suppresses pancreatic cancer progression through the interaction with macrophages in the tumor microenvironment

Kimura, G., Ijichi, H., Sano, M., Notoya, G., Miyabayashi, K., Takahashi, R., Kishikawa, T., & Mitsuhiro, F. (2025) · Scientific Reports · doi:10.1038/s41598-025-32222-4 · Cited by 2 · see citing works

The incidence and clinical features of familial pancreatic cancer in Korea

Kim, M., Kim, H., Han, Y., Sohn, H. J., Lee, M., Kang, Y. H., Kim, H. S., Kwon, W., & Jang, J. (2022) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.1117 · Cited by 2 · see citing works

Nanoparticles Bounded to Interfering RNAs as a Therapy for Pancreatic Cancer: A Systematic Review

Lara, P., Quiñonero, F., Ortíz, R., Prados, J. C., & Melguizo, C. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2013 · Cited by 2 · see citing works

Pancreatic Cancer Screening: A Narrative Review

Meziani, J., Fuhler, G. M., Bruno, M. J., Cahen, D. L., & Overbeek, K. A. (2024) · Techniques and Innovations in Gastrointestinal Endoscopy · doi:10.1016/j.tige.2024.08.001 · Cited by 2 · see citing works

Familial and Inherited Pancreatic Cancer

Kryklyva, V., Luchini, C., & Brosens, L. A. A. (2020) · Encyclopedia of pathology · doi:10.1007/978-3-319-28845-1_5508-1 · Cited by 2 · see citing works

Identification of DNA damage and repair gene-related markers in pancreatic ductal adenocarcinoma by single-cell and bulk RNA sequencing

Zhang, C.-Y., Tang, R., Yang, J., Chen, Y., Li, Y., Zhou, C., Wang, W., Yu, X., & Xu, J. (2025) · Discover Oncology · doi:10.1007/s12672-025-02293-w · Cited by 1 · see citing works

Assessment of barriers to pancreatic cancer surveillance in high‐risk individuals

Snyder, G., Clay, D., Karley, S., Pipito, S., Mueller, R., Bradbury, A. R., Maxwell, K. N., Nathanson, K. L., Rohanizadegan, M., Shah, P. D., et al. (2025) · Journal of Genetic Counseling · doi:10.1002/jgc4.70117 · Cited by 1 · see citing works

The Screening and Early Detection of Pancreatic Cancer: Who, When, and How?

Chang, J. H. (2020) · The Korean Journal of Pancreas and Biliary Tract · doi:10.15279/kpba.2020.25.2.65 · Cited by 1 · see citing works

Frühdiagnose des Pankreaskarzinoms – Die Rolle von Endosonografie und Sonografie

Schorr, F., & Essig, M. W. (2021) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1515-3123 · Cited by 1 · see citing works

Genetic features of pathogenesis in pancreatic adenocarcinomas

Набока, М. В., Garaev, T., Lyapustina, O. S., & Михайлович, В. Д. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-211-3-74-79 · Cited by 1 · see citing works

Gastrointestinal Cancer Precursor Conditions and Their Detection

Maoz, A., Rodriguez, N. J., Yurgelun, M. B. B., & Syngal, S. (2024) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.04.002 · Cited by 1 · see citing works

Circular RNA circXPO1 promotes multiple myeloma progression via sponging miR-495 3p and upregulating of DDIT4Preprint

Li, F., Liu, J., Miao, J., Hong, F., Lv, Y., Wu, D., Shen, Y., Liu, R., Zhang, R., Jia, Y., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1708285/v1 · Cited by 1 · see citing works

Interplay of Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans along with Circulating miR-21 and miR-155 as Potential Biomarkers for Pancreatic CancerPreprint

Hesami, Z., Olfatifar, M., Sadeghi, A., Mohammadi‐Yeganeh, S., Eghlimi, H., Pazienza, V., Hakemi-Vala, M., & Houri, H. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.21.655259 · Cited by 1 · see citing works

Clinical exome sequencing identified POLB c.C1002A as a possible genetic cause in a family with hereditary cancer-predisposing syndrome

Zhu, Z., Wang, J., Jiang, L., Lin, L., Meng, P., Zhao, J., & Cai, Q. (2020) · Cancer Genetics · doi:10.1016/j.cancergen.2020.06.003

The Increasing Proportion of Early-Stage Pancreatic Cancer between 2004–2013: A SEER Analysis

Oman, S. P., Corral, J. E., Stauffer, J. A., Raimondo, M., Mody, K., & Wallace, M. B. (2021) · Cancer Investigation · doi:10.1080/07357907.2021.1888386

Screening of Pancreatic Cancer for Early Diagnosis

Chang, J. H. (2021) · Korean Journal of Medicine · doi:10.3904/kjm.2021.96.2.110

Pancreatic Cancer Screening

Chalhoub, J. M., & Andrawes, S. (2021) · Clinical gastroenterology · doi:10.1007/978-3-030-69940-6_8

Risk Factors for Pancreatic Cancer and Cholangiocarcinoma

Hamada, T., & Nakai, Y. (2021) · Springer eBooks · doi:10.1007/978-981-16-2870-2_1

Reducing the Risk of and Screening for Pancreatic Cancer

Kothari, S., Kaul, V., & Kothari, T. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-37482-2_35-1

Pancreatic cancer with synchronous liver and colon metastases: A case report

Dong, Y.-M., Sun, H.-N., Sun, D., Deng, M., Peng, Y., & Zhu, Y.-Y. (2021) · World Journal of Clinical Cases · doi:10.12998/wjcc.v9.i33.10265

Reducing the Risk of and Screening for Pancreatic Cancer

Kothari, S., Kaul, V., & Kothari, T. H. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_35

Molecular and Genetic Profiling for the Diagnosis and Therapy of Hepatobiliary and Pancreatic Malignancies

Liang, H., Remstein, R., & LEWIS, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-41683-6_44

Familial and Inherited Pancreatic Cancer

Kryklyva, V., Luchini, C., & Brosens, L. A. A. (2022) · Encyclopedia of pathology · doi:10.1007/978-3-030-62416-3_5508

Data from EUS-based Pancreatic Cancer Surveillance in BRCA1/BRCA2/PALB2/ATM Carriers Without a Family History of Pancreatic Cancer

Katona, B. W., Long, J. M., Ahmad, N. A., Attalla, S., Bradbury, A. R., Carpenter, E. L., Clark, D. F., Constantino, G., Das, K. K., Domchek, S. M., et al. (2023) · doi:10.1158/1940-6207.c.6547030

Prevención y detección precoz del cáncer de páncreas

Lembach, H. (2024) · Revista Médica Clínica Las Condes · doi:10.1016/j.rmclc.2024.03.001

PROGNOSTIC IMPACT OF PROMOTER-HYPERMETHYLATED SFRP1 IN PANCREATIC DUCTAL ADENOCARCINOMA: A BLOOD-BASED BIOMARKER STUDY

Stubbe, B. E. (2024) · doi:10.54337/aau715865196

Familial Risk of Pancreatic Cancer and Interaction with Hyperglycemia, Smoking, and Obesity Among First-Degree Relatives: Identification of a High-Risk GroupPreprint

Kim, H. J., Kang, T., Swan, H., Kim, M. J., & Park, S. M. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4866714

Genetics and biology of pancreatic ductal adenocarcinoma

Jai, M., & Mozdziak, P. E. (2024) · Medical Journal of Cell Biology · doi:10.2478/acb-2024-0006

CC chemokine receptor 2 mediated regulation of macrophages is involved in pancreatic cancer progression in the tumor microenvironmentPreprint

Ijichi, H., Kimura, G., Sano, M., Notoya, G., Miyabayashi, K., Takahashi, R., Kishikawa, T., & Fujishiro, M. (2024) · Research Square · doi:10.21203/rs.3.rs-5124479/v1

Causal relationship and potential common pathogenic mechanisms between hidradenitis suppurativa and related cancer

Zhu, Z., & Wang, X. (2025) · Discover Oncology · doi:10.1007/s12672-025-02075-4

Diagnostic Dilemma

Roldan‐Vasquez, E., Cohen, S. M., & Kent, T. S. (2025) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2025.05.004

TFF2, a novel serum diagnostic biomarker for early pancreatic cancer

Wu, X., & Huang, X. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1633069

Familial risk of pancreatic cancer and interaction with hyperglycemia, smoking, and obesity among first-degree relatives

Kim, H.-J., Kang, T., Swan, H., & Park, S. M. (2025) · BMC Cancer · doi:10.1186/s12885-025-15252-z

ADAM17-dependent Autocrine and Paracrine Signaling Promotes Pancreatic Premalignant Progression

Wen, H.-J., Davis, E. T., Moore, J. S., Brender, S. M., Benitz, S., Wombwell, A. M., Loveless, I. M., Long, D. W., Salas-Escabillas, D. J., Lee, J., et al. (2025) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2025.101711

Additional file 1 of Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

Tavano, F., Gioffreda, D., Fontana, A., Palmieri, O., Gentile, A., Latiano, T., Latiano, A., Latiano, T. P., Scaramuzzi, M., Maiello, E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26564961

Additional file 2 of Evaluation of inherited germline mutations in cancer susceptibility genes among pancreatic cancer patients: a single-center study

Tavano, F., Gioffreda, D., Fontana, A., Palmieri, O., Gentile, A., Latiano, T., Latiano, A., Latiano, T. P., Scaramuzzi, M., Maiello, E., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26564964

Strategy for early diagnosis and prevention of pancreatic cancer

Осадчук, А. М., Osadchuk, M. M., & Loranskaya, I. D. (2025) · Russian Journal of Evidence-Based Gastroenterology · doi:10.17116/dokgastro20251404186

Implications oncogéniques des protéines SMAD2 & SMAD3 dans l’adénocarcinome canalaire pancréatique SMAD4-négatif

Bertrand‐Chapel, A. (2021) · theses.fr (ABES) · doi:10.70675/6f1078b7z94d3z4096z85a9z40b435cd6a59

Elucidation du rôle de la Ténascine-X dans la progression tumorale : focus sur la carcinogenèse pancréatique

Liot, S. (2021) · doi:10.70675/264bf0e9z97a7z4aaezaf51z5387f0dd8f4c

Targeting mitochondrial and redox metabolism to prevent relapse in pancreatic cancer

Hadi, N. A. (2022) · doi:10.70675/de0db041z7be5z4ee3z8a2cz7ca2e21ede31

Role of the stromal microenvironment in PDAC and resistance to therapies

Ode, A. (2024) · doi:10.70675/0452e0e9z98e8z47d9za007zd4b472926aab

A Novel Emerin/Nesprin-3 Interaction Mediates Nuclear Size Changes Induced by Oncogenic KRAS in Pancreatic Cancer Cells

LaRue-Nolan, K. C., Flores, L. F., Vera, R. E., Sigafoos, A. N., Hilario-Garcia, L., Almada, L. L., Tader, B. R., Rodriguez-Quevedo, M. F., May, D. G., Marks, D. L., et al. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2026.2670710

Trends and projections of pancreatic cancer mortality in US adults by sex, race and ethnicity, region, and urbanization: a national analysis of CDC WONDER data, 1999–2050Preprint

Atif, K., Atif, E., Das, V., Ahmad, A., Ali, M., Hassan, M. A., Fatima, K., Qazi, S., Mazhar, M. A., Kutbi, E., et al. (2026) · Research Square · doi:10.21203/rs.3.rs-10293977/v1

The Emerging Genetic Basis and Its Clinical Implication in Pancreatic Cancer

Chen, F., Guo, Y., & Wang, L. (2015) · Gastrointestinal Tumors · doi:10.1159/000435764

New Developments in the Molecular Mechanisms of Pancreatic Tumorigenesis

Felsenstein, M., Hruban, R. H., & Wood, L. D. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000172 · Cited by 54 · see citing works

Genetic Basis of Pancreas Cancer Development and Progression: Insights from Whole-Exome and Whole-Genome Sequencing

Iacobuzio–Donahue, C. A., Velculescu, V. E., Wolfgang, C. L., & Hruban, R. H. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0315 · Cited by 149 · see citing works

Pancreatic Carcinogenesis

Koorstra, J.-B. M., Hustinx, S. R., Offerhaus, G. J. A., & Maitra, A. (2008) · Pancreatology · doi:10.1159/000123838 · Cited by 180 · see citing works

Familial and sporadic pancreatic cancer share the same molecular pathogenesis

Norris, A. L., Roberts, N. J., Jones, S., Wheelan, S. J., Papadopoulos, N., Vogelstein, B., Kinzler, K. W., Hruban, R. H., Klein, A. P., & Eshleman, J. R. (2014) · Familial Cancer · doi:10.1007/s10689-014-9755-y · Cited by 57 · see citing works